title: Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
abstract: We have treated 25 consecutive patients with advanced ovarian carcinoma with cisplatin (100 mg/m2 iv on Day 1) and etoposide (100 mg/m2 orally on Days 1-3) every 3 weeks. All patients had failed previous treatment with doxorubicin and cyclophosphamide and had bulky abdominal disease. Complete response was achieved in one of 25 patients (4%), partial response was achieved in nine of 25 patients (36%), and stable disease was obtained in six additional patients (24%). Median time to disease progression was 6.8 months. Toxicity was acceptable. Cisplatin and etoposide is an effective second-line treatment of ovarian carcinoma.
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D005047:Etoposide; D002945:Cisplatin